2017
DOI: 10.1093/intimm/dxx052
|View full text |Cite
|
Sign up to set email alerts
|

Expression of KIR2DS1 does not significantly contribute to NK cell cytotoxicity in HLA-C1/C2 heterozygous haplotype B donors

Abstract: NK cells are functionally controlled by the killer immunoglobulin-like receptor (KIR) family that comprises inhibitory (iKIR) and activating (aKIR) members. Genetic association studies suggest that donors expressing aKIRs next to iKIRs will be superior donors in the setting of hematopoietic stem cell transplantation of patients with leukemia. However, contrary evidence states that aKIR expression may be irrelevant or even detrimental. Using a complex methodology incorporating KIR-Q-PCR, double fluorescence and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 40 publications
0
3
0
Order By: Relevance
“…HLA-C allotypes, including the C1 or the C2 epitope, act as ligands for KIRs. Inhibitory KIR2DL1 receptors and activating KIR2DS1 receptors bind to the C2 epitope, while inhibitory KIR2DL2/3 receptors bind to the C1 epitope ( 47 , 48 ). The binding strength of inhibitory receptors is higher than that of activating receptors upon binding to the same epitope.…”
Section: Kir/hla Interactionsmentioning
confidence: 99%
“…HLA-C allotypes, including the C1 or the C2 epitope, act as ligands for KIRs. Inhibitory KIR2DL1 receptors and activating KIR2DS1 receptors bind to the C2 epitope, while inhibitory KIR2DL2/3 receptors bind to the C1 epitope ( 47 , 48 ). The binding strength of inhibitory receptors is higher than that of activating receptors upon binding to the same epitope.…”
Section: Kir/hla Interactionsmentioning
confidence: 99%
“…Considering the particular susceptibility of patients with leukemia undergoing myeloablative conditioning regimens to subsequent CMV infection, it is theoretically attractive to exploit adaptive NK cells of CMV‐positive individuals not only to boost antiviral immunity but more so to make use of the theoretically achievable expansion of the in fact minute alloreactive KIR2DS1 + NK cell subset in HLA‐C1/C2 donors which is highly responsive toward C2‐expressing targets . With this intention, a phase I clinical trial in AML patients has been initiated by Sarah Cooley and colleagues, which will determine the maximal tolerated dose (MTD) of so‐called FATE‐NK100 cells (NK cells of a donor previously exposed to CMV) in conjunction with IL‐2 and combination chemotherapy (NCT03081780, Table ).…”
Section: Efficacy Of Memory‐like Nk Cellsmentioning
confidence: 99%
“…Natural killer (NK) cells are an important component of the innate immune system, they are typically cluster of differentiation (CD)3 − CD56 + cells, which and are primarily distributed in the peripheral blood, with 10–15% in lymphocytes ( 17 , 18 ). NK cells are responsible for immune surveillance without antigen presentation and major histocompatibility complex (MHC) restriction ( 19 ). Once activated, NK cells are able to recognize target cells rapidly and release cytotoxic effector molecules to trigger the immune response ( 20 ).…”
Section: Introductionmentioning
confidence: 99%